Haywood Reiterates Lundin Mining’s $12 Price Target Following Josemaria Acquisition

On December 20th, Lundin Mining (TSX: LUN) announced that they would be acquiring Josemaria Resources (TSX: JOSE) for C$625 million, or US$485 million. The deal is broken down that for every share of Josemaria Resources, shareholders can receive 0.1487 shares of Lundin Mining or C$1.60 in cash. The total cash consideration can only be equal to $183 million or 30% of the total consideration.

Lundin Mining says that the acquisition would provide Lundin investors with “large-scale copper-gold growth,” while increasing their copper production by almost 50% and gold production by 140%. They also say that the deal significantly reduces capital financing risks for Josemaria’s project timelines.

Lundin Mining currently has 20 analysts covering the stock with an average 12-month price target of C$11.68, or a 23% upside to the current stock price. Out of the 20 analysts, 2 have strong buy ratings, 5 have buys, 12 analysts have hold ratings and 1 analyst has a sell rating on Lundin Mining. The street high sits at C$14.75 while the lowest comes in at C$8.56.

In Haywood Capital Markets’ note, they reiterate their C$12 12-month price target and hold rating, saying that Rosemaria, “provides a welcome diversification from LUN’s existing portfolio,” but warns that this will be management’s biggest challenge to date.

Haywood sounds like they are not too surprised by this transaction, saying that Josemaria is a Lundin company and shows the overlap between Lundin Mining C-suite and Josemaria’s C-suite, as well as they point to the fact that the Lundin family and Lorito Holdings own roughly 42% of Josemaria Resources.

Josemaria owns a major copper-gold asset which contains 1.0 billion tonnes grading 0.3% copper, 0.22 g/t gold and 0.94 g/t silver. Haywood says that the 2020 feasibility shows an average annual production of 130,000 tons of copper, 225,000 ounces of gold, and 1 million ounces of silver.

Haywood puts a loose production date of 2026 for Josemaria’s assets. They believe that the Environmental Impact Assessment and Fiscal Stability Agreement is to be done in early 2022, which means they could have a construction decision by the second half of 2022.

Lastly, Haywood says that this acquisition has the potential for significant NAV upside, as they have not included Josemaria numbers into their NAV. They say that based on their long-term copper and gold price of $4.15 per pound and $1,8000 per ounce, he project has an NPV of $3.2 billion and an IRR of 22%.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

This Could Be the Next Multi-Million Ounce Gold Camp | Mike Bennett

Newmont Stock Drops Despite Massive Cash Flow — Here’s Why | Q4 Earnings

Strongest Gold Bull Market in 30 Years — And It’s Global | Michael Dehn

Recommended

Advanced Gold Acquires Nevada Property With Historic Production At 1,611 g/t Silver

Steadright: Atrium Research Initiates Coverage With $0.50 Price Target

Related News

Coinbase: Canaccord Initiates Coverage With $285 Price Target

Coinbase Global (NASDAQ: COIN) has been initiated by another large analyst firm. This time it’s...

Thursday, June 17, 2021, 03:46:00 PM

Medipharm Labs: Canaccord Lowers Targets After Earnings

On August 16, Medipharm Labs (TSX: LABS) reported their second quarter financial results. The company...

Friday, August 20, 2021, 07:54:00 AM

Equinox: BMO Lowers Price Target To $14.50 Follow Mercedes Mine Sale

On December 17th, Equinox Gold (TSX: EQX) announced that they reached an agreement to sell...

Tuesday, December 28, 2021, 11:06:00 AM

PharmaTher: Maxim Initiates Coverage With US$1.50 Price Target

PharmaTher Holdings (CSE: PHRM) had its first initiation report that came out on June 28th....

Wednesday, June 30, 2021, 02:38:00 PM

Antibe Therapeutics: Canaccord Upgrades Price Target To $16.50

Earlier this week, Antibe Therapeutics (TSXV: ATE) announced a strategic licensing deal with Nuance Pharm...

Thursday, February 11, 2021, 04:07:00 PM